← Back to Clinical Trials
Recruiting NCT07047846

NCT07047846 Bowen Technique Versus Dynamic Soft Tissue Mobilization on Pain, Range of Motion and Functional Disability in Patients With Adhesive Capsulitis

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07047846
Status Recruiting
Phase
Sponsor University of Lahore
Condition Adhesive Capsulitis
Study Type INTERVENTIONAL
Enrollment 72 participants
Start Date 2025-07-16
Primary Completion 2025-09-10

Eligibility & Interventions

Sex All sexes
Min Age 50 Years
Max Age 80 Years
Study Type INTERVENTIONAL
Interventions
Dynamic soft tissue mobilizationBowen Technique and 3 moves

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 72 participants in total. It began in 2025-07-16 with a primary completion date of 2025-09-10.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

A randomized controlled trial included 72 patients diagnosed with adhesive capsulitis will conduct in University of Lahore Teaching Hospital. The study will complete within 9 months after the approval of synopsis. Patients who fulfilled the inclusion criteria will identified by individual physiotherapist and will enrolled for particular study. Informed written consent will be taken by the patients and will randomly allocated into two groups. The total numbers of sessions will 12 (3 sessions per week). The study will single blinded. The assessor will unaware of the treatment given to both groups. Control group received routine physical therapy with dynamic soft tissue mobilization technique. thermotherapy, trans-cutaneous electrical nerve stimulation, shoulder isometrics and stretching that includes 12 sessions and three times per week. Experimental group received routine physical therapy along with Bowen technique. This includes thermotherapy, trans-cutaneous electrical nerve stimulation, shoulder isometrics and stretching that includes 12 sessions and three times per week

Eligibility Criteria

Inclusion Criteria: * Diagnosed patients of 50-80 years of age * Grade 2 \& 3 (frozen and thawing) adhesive capsulitis * patients willing to participate in the study * Only diabetic patients Exclusion Criteria: * Major mental health probleme * Patients who has a history of surgery on the shoulder, other shoulder diseases including a rotator cuff tear, sub acromial impingement syndrome, and a shoulder labral tear * Patients taking oral or intra-articular steroids and cortisone injection prior 3 months * Subjects with rotator cuff tears or other shoulder ligament injuries, H/O arthritis related to shoulder, malignancy, adhesive capsulitis secondary to fractures, dislocation, reflex sympathetic dystrophy, neurological disorder

Contact & Investigator

Central Contact

Dr farrukh Murtaza Physical Therapist, Phd (PT)*

✉ Farrukh.murtaza@uipt.uol.edu.pk

📞 +923339970563

Frequently Asked Questions

Who can join the NCT07047846 clinical trial?

This trial is open to participants of all sexes, aged 50 Years or older, up to 80 Years, studying Adhesive Capsulitis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07047846 currently recruiting?

Yes, NCT07047846 is actively recruiting participants. Contact the research team at Farrukh.murtaza@uipt.uol.edu.pk for enrollment information.

Where is the NCT07047846 trial being conducted?

This trial is being conducted at Lahore, Pakistan.

Who is sponsoring the NCT07047846 clinical trial?

NCT07047846 is sponsored by University of Lahore. The trial plans to enroll 72 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology